ATOS
Price
$0.69
Change
+$0.04 (+6.15%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
88.82M
46 days until earnings call
NTLA
Price
$7.30
Change
+$0.64 (+9.61%)
Updated
Apr 2 closing price
Capitalization
755.68M
28 days until earnings call
Ad is loading...

ATOS vs NTLA

Header iconATOS vs NTLA Comparison
Open Charts ATOS vs NTLABanner chart's image
Atossa Therapeutics
Price$0.69
Change+$0.04 (+6.15%)
Volume$3.27K
Capitalization88.82M
Intellia Therapeutics
Price$7.30
Change+$0.64 (+9.61%)
Volume$5.37M
Capitalization755.68M
ATOS vs NTLA Comparison Chart
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. NTLA commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Buy and NTLA is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (ATOS: $0.69 vs. NTLA: $7.30)
Brand notoriety: ATOS and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 90% vs. NTLA: 156%
Market capitalization -- ATOS: $88.82M vs. NTLA: $755.68M
ATOS [@Biotechnology] is valued at $88.82M. NTLA’s [@Biotechnology] market capitalization is $755.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATOS and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • ATOS’s TA Score: 4 bullish, 4 bearish.
  • NTLA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ATOS is a better buy in the short-term than NTLA.

Price Growth

ATOS (@Biotechnology) experienced а -1.25% price change this week, while NTLA (@Biotechnology) price change was -12.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.26%. For the same industry, the average monthly price growth was -7.43%, and the average quarterly price growth was -11.99%.

Reported Earning Dates

ATOS is expected to report earnings on May 19, 2025.

NTLA is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-5.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($756M) has a higher market cap than ATOS($88.8M). ATOS YTD gains are higher at: -31.045 vs. NTLA (-37.393). ATOS has higher annual earnings (EBITDA): -29.46M vs. NTLA (-523.98M). NTLA has more cash in the bank: 602M vs. ATOS (74.8M). ATOS has less debt than NTLA: ATOS (0) vs NTLA (210M). NTLA has higher revenues than ATOS: NTLA (57.9M) vs ATOS (0).
ATOSNTLAATOS / NTLA
Capitalization88.8M756M12%
EBITDA-29.46M-523.98M6%
Gain YTD-31.045-37.39383%
P/E RatioN/AN/A-
Revenue057.9M-
Total Cash74.8M602M12%
Total Debt0210M-
FUNDAMENTALS RATINGS
ATOS vs NTLA: Fundamental Ratings
ATOS
NTLA
OUTLOOK RATING
1..100
5558
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
9095
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (26) in the Biotechnology industry is in the same range as ATOS (28) in the Medical Specialties industry. This means that NTLA’s stock grew similarly to ATOS’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that NTLA’s stock grew similarly to ATOS’s over the last 12 months.

ATOS's SMR Rating (96) in the Medical Specialties industry is in the same range as NTLA (97) in the Biotechnology industry. This means that ATOS’s stock grew similarly to NTLA’s over the last 12 months.

ATOS's Price Growth Rating (90) in the Medical Specialties industry is in the same range as NTLA (95) in the Biotechnology industry. This means that ATOS’s stock grew similarly to NTLA’s over the last 12 months.

ATOS's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as NTLA (100) in the Biotechnology industry. This means that ATOS’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSNTLA
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 17 days ago
81%
Bullish Trend 10 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VGORX51.32N/A
N/A
Voya Large-Cap Growth R
VPADX89.86N/A
N/A
Vanguard Pacific Stock Index Admiral
BBISX31.02N/A
N/A
Sterling Capital Behav Lg Cp Val Eq Intl
PLLAX23.46N/A
N/A
Principal SmallCap A
JSJFX14.95N/A
N/A
JHancock Small Cap Dynamic Growth R6

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with ABOS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-3.25%
ABOS - ATOS
48%
Loosely correlated
-2.27%
ABCL - ATOS
43%
Loosely correlated
-6.28%
AXON - ATOS
42%
Loosely correlated
+2.90%
GBIO - ATOS
41%
Loosely correlated
-9.11%
NTLA - ATOS
41%
Loosely correlated
-6.40%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+9.69%
VCYT - NTLA
69%
Closely correlated
+1.93%
CRSP - NTLA
62%
Loosely correlated
+3.17%
BEAM - NTLA
62%
Loosely correlated
+4.79%
RXRX - NTLA
58%
Loosely correlated
+3.83%
FATE - NTLA
57%
Loosely correlated
+1.70%
More